List of Excipients in Branded Drug HYDROCORTISONE SODIUM SUCCINATE

Generic Drugs Containing HYDROCORTISONE SODIUM SUCCINATE

Company	Ingredient	NDC	Excipient
Apotex Corp	hydrocortisone sodium succinate	60505-6411	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Apotex Corp	hydrocortisone sodium succinate	60505-6411	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Cipla USA Inc	hydrocortisone sodium succinate	69097-004	SODIUM HYDROXIDE
Cipla USA Inc	hydrocortisone sodium succinate	69097-004	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
Cipla USA Inc	hydrocortisone sodium succinate	69097-004	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Zydus Pharmaceuticals USA Inc	hydrocortisone sodium succinate	70710-1907	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS

What are the Most Frequently-Used Excipients in HYDROCORTISONE SODIUM SUCCINATE?

# Of NDCs	Excipient
1	SODIUM HYDROXIDE
4	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
4	SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

Hydrocortisone Sodium Succinate Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Hydrocortisone sodium succinate is an established injectable corticosteroid with limited active-ingredient differentiation and substantial opportunity in formulation execution. The strongest commercial positions are likely to come from reliable sterile manufacturing, rapid reconstitution, ready-to-use presentations, preservative-free products, differentiated packaging, and supply performance rather than from new chemical composition claims.

The product is used when parenteral corticosteroid therapy is required, including adrenal insufficiency, severe allergic reactions, inflammatory disease, and perioperative or emergency care. Pfizer markets the reference product Solu-Cortef, while generic products are approved through abbreviated new drug applications. The principal commercial risk is price competition in a mature hospital market. The principal opportunity is reducing preparation burden and stock-out exposure.

What is hydrocortisone sodium succinate and how is it formulated?

Hydrocortisone sodium succinate is a water-soluble ester prodrug of hydrocortisone designed for injection. After administration, it is hydrolyzed to active hydrocortisone. Its sodium succinate group improves aqueous solubility compared with hydrocortisone itself.

The product is marketed primarily as:

• Sterile lyophilized powder requiring reconstitution
• Dual-chamber or vial-with-diluent systems
• Reconstituted injectable solution
• Intravenous or intramuscular presentations
• Multiple strengths, commonly 100 mg, 250 mg, 500 mg, and 1,000 mg hydrocortisone equivalent

The reference product’s Act-O-Vial system separates the drug powder from the diluent until use. This configuration improves shelf stability and allows rapid bedside preparation. FDA labeling identifies the active ingredient as hydrocortisone sodium succinate equivalent to the labeled amount of hydrocortisone [1].

Why is a prodrug used instead of hydrocortisone?

Hydrocortisone has limited aqueous solubility. Converting it to the sodium succinate ester enables preparation of a sterile injectable product suitable for intravenous administration. The formulation must preserve the ester during storage while allowing conversion to hydrocortisone after administration.

This creates several development priorities:

1. High aqueous solubility after reconstitution
2. Controlled pH
3. Low particulate burden
4. Acceptable reconstitution time
5. Chemical stability of the succinate ester
6. Consistent potency across the labeled shelf life
7. Compatibility with intravenous administration and common infusion systems

What excipients are used in hydrocortisone sodium succinate injections?

Excipients vary by manufacturer, strength, container system, and dosage form. Common formulation functions include buffering, pH adjustment, tonicity control, and reconstitution.

Excipient function	Typical formulation objective	Commercial relevance
Buffering agent	Maintain pH during storage and reconstitution	Supports chemical stability and consistent injection performance
Sodium hydroxide or acid	Adjust final pH	Controls solubility, degradation, and tolerability
Water for injection	Reconstitute the lyophilized cake	Determines ease of preparation and final concentration
Tonicity modifier	Reduce injection discomfort or support infusion compatibility	More relevant in ready-to-use solutions
Chelating or stabilizing component	Limit trace-metal or oxidation effects where justified	Requires strong compatibility and safety data
Preservative	Control microbial growth in multidose products	Creates regulatory and tolerability trade-offs
Nitrogen or controlled headspace	Limit oxidative stress	Relevant to liquid products and container closure design

The reference Solu-Cortef presentation uses a powder-and-diluent configuration. Excipients and inactive ingredients must be confirmed against the current product label because they can differ among reference, generic, and international products [1, 2].

What excipient issues are specific to hydrocortisone sodium succinate?

The most important issue is the balance between solubility and chemical stability. A pH that improves solubility may increase degradation or alter the impurity profile. A formulation that is too concentrated may create reconstitution or precipitation problems. A formulation that is too dilute increases package volume, shipping cost, and administration burden.

The product also requires control of:

• Ester hydrolysis
• Oxidative degradation
• pH drift
• Visible and subvisible particulates
• Reconstitution-related foaming
• Adsorption to infusion materials
• Container closure extractables and leachables
• Microbial contamination after reconstitution

The excipient strategy should therefore be developed together with the lyophilization cycle, vial geometry, stopper selection, and labeled in-use period. Excipients cannot be optimized independently from the primary container and manufacturing process.

What is the best excipient strategy for a generic hydrocortisone sodium succinate product?

A commercially strong formulation would generally prioritize a simple, label-compatible composition with a reliable sterile process. The formulation should avoid unnecessary excipients because the product is administered in acute-care settings and may be used in patients with limited clinical information.

Strategy 1: Reference-like lyophilized powder

A reference-like powder formulation is the lowest-risk entry strategy. It can use a conventional vial, sterile diluent, and established lyophilization process.

Advantages include:

• Familiar regulatory pathway
• Straightforward qualitative and quantitative comparison
• Lower excipient novelty risk
• Compatibility with existing hospital procedures
• Easier positioning as a direct generic substitute

The disadvantages are preparation time, handling errors, and dependence on reconstitution by clinical staff.

Strategy 2: Preservative-free single-dose vial

A preservative-free single-dose vial is commercially attractive for emergency departments, intensive-care units, operating rooms, neonatal care, and patients vulnerable to preservative exposure.

This format may command a modest preference where institutional policies favor preservative-free injections. The trade-off is that single-dose packaging increases unit consumption and requires tighter aseptic manufacturing controls.

Strategy 3: Ready-to-use liquid injection

A ready-to-use solution can reduce preparation time and medication errors. It may be attractive for emergency carts, ambulances, operating rooms, and hospital formularies seeking standardized administration.

The technical barriers are higher:

• Long-term solution stability
• Ester hydrolysis
• Oxidation
• Container compatibility
• Sterility maintenance
• Precipitation risk
• Acceptable osmolality and pH
• Longer-term extractables and leachables assessment

A ready-to-use product is more differentiated than a powder vial but may require a more complex regulatory and stability package.

Strategy 4: Dual-chamber syringe or cartridge

A dual-chamber system preserves the stability advantages of a dry product while reducing bedside preparation steps. The system can be designed for rapid activation and administration.

Commercial barriers include device development, combination-product requirements, human-factors testing, manufacturing complexity, and higher packaging cost. The approach is most relevant where speed and preparation reliability have measurable value.

What formulations are protected by patents?

The core composition and conventional injectable presentation are mature technologies. The original composition-of-matter and basic product patents associated with hydrocortisone sodium succinate are long expired. Commercial differentiation is more likely to involve formulation, container, device, manufacturing process, or use claims than the active ingredient itself.

Potentially protectable areas include:

• Stabilized liquid formulations
• Specific pH and buffer systems
• Low-impurity lyophilized cakes
• Rapid-reconstitution systems
• Dual-chamber containers
• Prefilled syringes
• Autoinjectors
• Extended in-use stability after reconstitution
• Compatibility with infusion systems
• Manufacturing processes that improve cake structure or impurity control

A new patent position would need a meaningful technical distinction. A routine substitution of one conventional buffer for another is unlikely to provide strong commercial protection unless it produces an unexpected stability, reconstitution, compatibility, or clinical-use benefit.

What is the FDA regulatory status of hydrocortisone sodium succinate?

Hydrocortisone sodium succinate injection is an established FDA-approved prescription drug. The reference product is Solu-Cortef, marketed by Pfizer. Generic products may be approved under ANDAs referencing the relevant reference listed drug [1, 3].

The main regulatory considerations are:

• Sterile injectable manufacturing under current good manufacturing practice
• Demonstration of pharmaceutical equivalence
• Demonstration of bioequivalence where applicable
• Matching strength and route of administration
• Control of visible and subvisible particulates
• Sterility and endotoxin testing
• Container closure integrity
• Reconstitution and in-use stability
• Labeling of storage conditions and handling procedures

For a conventional injectable solution or powder, the regulatory pathway is more predictable than for a novel delivery system. A device-enabled product may introduce combination-product and human-factors requirements.

What is the Orange Book status of hydrocortisone sodium succinate?

The Orange Book identifies FDA-approved reference products and approved generic equivalents. The commercial importance of Orange Book listings is primarily substitution and regulatory reference, not patent exclusion, because the foundational exclusivity period for hydrocortisone sodium succinate has expired [3].

For a generic applicant, the relevant business questions are:

• Which reference listed drug is being cited?
• Does the proposed product match the reference strength and dosage form?
• Are there listed patents or exclusivity codes affecting the product?
• Does the product have therapeutic equivalence coding that supports pharmacy substitution?
• Are multiple approved suppliers available?

Patent certification risk is generally lower for this mature product than for a recently approved drug. Paragraph IV litigation may arise if a later entrant relies on a listed formulation or device patent, but a conventional hydrocortisone sodium succinate vial is more likely to compete on manufacturing, quality, and price.

When does hydrocortisone sodium succinate lose exclusivity?

The foundational exclusivity for hydrocortisone sodium succinate has already expired. Solu-Cortef is a legacy product, and the market contains generic competition.

The relevant commercial protection is therefore not exclusivity in the traditional sense. It is the combination of:

• FDA approval
• Manufacturing capacity
• Reliable sterile fill-finish operations
• Hospital contracting
• Distribution reach
• Product availability
• Formulation or device differentiation
• Regulatory compliance history

A new entrant cannot rely on market exclusivity to support premium pricing. It must establish a cost or service advantage.

Which companies are challenging the reference product?

Generic pharmaceutical companies have entered the hydrocortisone sodium succinate injection market through ANDA approvals. The competitive set can change as products enter, leave, or experience supply interruptions. FDA approval records and the Orange Book provide the authoritative product-level information [3].

The market is generally characterized by:

• Pfizer as reference-product sponsor
• Generic injectable manufacturers
• Contract manufacturers and specialty sterile suppliers
• Hospital distributors and group purchasing organizations
• Potential private-label or institutional suppliers

Competition is often influenced by manufacturing continuity rather than by brand promotion. A supplier with fewer back-up sites may be vulnerable to plant shutdowns, quality holds, or constrained access to sterile components.

What generic entry risks exist for hydrocortisone sodium succinate?

The main risks are operational.

Sterile manufacturing risk

Injectable corticosteroids require validated aseptic processing, environmental controls, container closure integrity, and reliable visual inspection. A quality event can remove a supplier from hospital contracts quickly.

Supply-chain risk

Key vulnerabilities include:

• Sterile vial and stopper availability
• Lyophilization capacity
• API supply qualification
• Packaging component changes
• Testing laboratory capacity
• Dependence on a single manufacturing site

Price erosion

Multiple approved suppliers can compress margins, especially for standard 100 mg and 250 mg vials. A differentiated presentation may reduce direct price comparison but will not eliminate hospital purchasing pressure.

Substitution and contracting risk

A product may be FDA-approved but still have limited commercial uptake if it lacks:

• Therapeutic-equivalence positioning
• Distributor availability
• GPO access
• Hospital formulary acceptance
• Reliable allocation performance

How large is the commercial opportunity?

The opportunity is best understood as a portfolio opportunity rather than a single-product opportunity. Hydrocortisone sodium succinate has recurring demand because it is used in emergency medicine, critical care, perioperative treatment, endocrinology, and inpatient care.

The strongest segments are likely to be:

Segment	Commercial need	Suitable product strategy
Emergency departments	Speed and low preparation burden	Ready-to-use vial or dual-chamber system
Intensive-care units	Reliable supply and flexible dosing	Multiple strengths and preservative-free vials
Operating rooms	Rapid access and standardized preparation	Single-dose vial or activated syringe
Ambulance and emergency kits	Compact storage and rapid administration	Stable vial-diluent or autoinjector
Pediatric and neonatal care	Low excipient burden and dosing flexibility	Preservative-free, low-volume presentation
Hospitals with shortage exposure	Supply continuity	Dual-source manufacturing and inventory services
International markets	Affordable injectable corticosteroid access	Cost-optimized powder vial

Revenue exposure is concentrated in institutional channels. Retail pharmacy is less important than hospital distribution, government procurement, emergency-care contracts, and specialty wholesalers.

How can excipient selection create commercial differentiation?

Excipient selection can support differentiation when it produces a measurable product benefit.

High-value claims may include:

• Faster reconstitution
• Longer post-reconstitution stability
• Lower particulate formation
• Improved compatibility with common infusion solutions
• Lower residual moisture
• Better cake appearance and dose recovery
• Reduced preparation steps
• Preservative-free status
• Lower extractables and leachables burden
• Improved storage tolerance

The strongest development program would link each excipient choice to a validated performance metric. For example, a buffer system should be evaluated against potency retention, impurity growth, reconstitution time, pH drift, and particulate formation rather than selected only because it is common in injectable products.

How does hydrocortisone sodium succinate compare with competing corticosteroid injections?

Product	Active ingredient	Main formulation profile	Commercial distinction
Hydrocortisone sodium succinate	Hydrocortisone prodrug	Water-soluble injectable powder or solution	Strong role in adrenal replacement and emergency corticosteroid therapy
Methylprednisolone sodium succinate	Methylprednisolone prodrug	Water-soluble injectable powder or solution	Broader corticosteroid potency and different clinical positioning
Dexamethasone sodium phosphate	Dexamethasone prodrug	Usually ready-to-use solution	High potency and lower mineralocorticoid activity
Prednisolone sodium phosphate	Prednisolone prodrug	Injectable or oral liquid depending on product	Different potency and clinical use profile

Hydrocortisone sodium succinate cannot be differentiated solely by corticosteroid activity. Its commercial position depends on clinical preference, mineralocorticoid activity, institutional protocols, dosing familiarity, and availability.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve technology and supply than basic active-ingredient rights.

Potential partnership models include:

• Licensing a ready-to-use injectable platform
• Contract development of a stable liquid formulation
• Co-development of a dual-chamber delivery system
• Regional commercialization rights
• Hospital-focused private-label supply
• Secondary manufacturing-site agreements
• API and finished-dose supply arrangements
• Distribution partnerships for emerging markets

A licensee should value the partner’s sterile manufacturing record, regulatory history, device capabilities, and supply redundancy. A formulation patent without commercial-scale sterile production may have limited value.

What manufacturing and IP barriers matter most?

Manufacturing barriers are more significant than core composition patents.

Important barriers include:

• Development of a robust lyophilization cycle
• Control of residual moisture
• Sterile powder filling
• Reproducible reconstitution
• Stability-indicating analytical methods
• Control of succinate-related impurities
• Container closure integrity
• Validated aseptic process simulation
• Scale-up without cake collapse or dose variability

The most defensible IP may combine formulation and process claims. A patent directed only to a conventional buffer may be weak, while a patent linked to improved stability under defined conditions, rapid reconstitution, and reduced impurity generation may have greater value.

What is the likely generic launch scenario?

A conventional generic powder vial would likely enter through price competition and hospital contracting. A differentiated ready-to-use or device-enabled product could launch later at a premium, provided the operational benefit is clear enough to justify procurement changes.

Three launch paths are commercially plausible:

1. Low-cost conventional generic with broad distributor coverage
2. Premium preservative-free or ready-to-use product for acute-care settings
3. Dual-source institutional strategy combining standard vials with differentiated emergency packaging

The lowest-risk route is a reference-like vial. The highest-value route is a differentiated presentation supported by a credible supply-continuity program.

Key Takeaways

• Hydrocortisone sodium succinate is a mature injectable corticosteroid with expired foundational exclusivity.
• Excipients primarily support pH control, solubility, chemical stability, tonicity, and reconstitution.
• The most attractive formulation opportunities are preservative-free products, ready-to-use solutions, and dual-chamber delivery systems.
• Commercial success depends more on sterile manufacturing reliability, hospital contracting, and supply continuity than on core API IP.
• New patent value is most credible where formulation changes produce measurable stability, reconstitution, compatibility, or device benefits.
• Conventional generic entry is feasible but exposed to price erosion and hospital procurement pressure.
• A differentiated product should target emergency departments, intensive care, operating rooms, ambulances, and institutions exposed to injectable supply disruptions.

FAQs

Is hydrocortisone sodium succinate the same as hydrocortisone?

No. Hydrocortisone sodium succinate is a water-soluble ester prodrug that is converted to hydrocortisone after administration.

Can hydrocortisone sodium succinate be supplied as a prefilled syringe?

Yes, a prefilled or dual-chamber syringe is technically possible, but it requires device compatibility, stability, human-factors, and combination-product development.

Are preservatives necessary in hydrocortisone sodium succinate injections?

Not necessarily. Single-dose preservative-free presentations are commercially and clinically attractive, while multidose products may require antimicrobial preservation depending on the container and labeling strategy.

Which excipient is most important for product stability?

No single excipient determines stability. Buffer selection, pH, residual moisture, oxygen exposure, container closure, and lyophilization conditions must be optimized together.

Can a new hydrocortisone sodium succinate formulation receive patent protection?

Yes, if it has a novel and non-obvious formulation, process, container, or delivery-system feature that produces a defensible technical benefit. Routine excipient substitution is less likely to support strong protection.

References

1. Pfizer Inc. (2023). Solu-Cortef (hydrocortisone sodium succinate) for injection prescribing information. U.S. Food and Drug Administration labeling database.

2. U.S. Food and Drug Administration. (2024). DailyMed: Hydrocortisone sodium succinate injection product labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA Center for Drug Evaluation and Research.